93 related articles for article (PubMed ID: 21948230)
1. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.
Smith CC; Shah NP
Clin Cancer Res; 2011 Nov; 17(21):6605-7. PubMed ID: 21948230
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.
Stein AM; Bottino D; Modur V; Branford S; Kaeda J; Goldman JM; Hughes TP; Radich JP; Hochhaus A
Clin Cancer Res; 2011 Nov; 17(21):6812-21. PubMed ID: 21903771
[TBL] [Abstract][Full Text] [Related]
3. AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells.
Nieborowska-Skorska M; Flis S; Skorski T
Leukemia; 2014 Dec; 28(12):2416-8. PubMed ID: 25151958
[No Abstract] [Full Text] [Related]
4. Overcoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2.
Cogle CR
J Natl Cancer Inst; 2013 Mar; 105(6):378-9. PubMed ID: 23446756
[No Abstract] [Full Text] [Related]
5. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.
Tang M; Gonen M; Quintas-Cardama A; Cortes J; Kantarjian H; Field C; Hughes TP; Branford S; Michor F
Blood; 2011 Aug; 118(6):1622-31. PubMed ID: 21653938
[TBL] [Abstract][Full Text] [Related]
8. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
9. The challenges of targeting chronic myeloid leukemia stem cells.
Jiang X; Smith C; Eaves A; Eaves C
Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 2():S71-80. PubMed ID: 17382016
[TBL] [Abstract][Full Text] [Related]
10. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
[TBL] [Abstract][Full Text] [Related]
12. Inviting leukemic cells to waltz with the devil.
Melo J
Nat Med; 2001 Feb; 7(2):156-7. PubMed ID: 11175841
[No Abstract] [Full Text] [Related]
13. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
[TBL] [Abstract][Full Text] [Related]
14. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
15. [Study on the mechanisms of imatinib-resistance of cancer stem-like cells in K562/Vp16 cell line].
Song YP; Fang BJ; Wei XD; Zheng S
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):669-73. PubMed ID: 16620554
[TBL] [Abstract][Full Text] [Related]
16. Dodging the magic bullet: understanding imatinib resistance.
Daley GQ
Cancer Biol Ther; 2003; 2(1):109-10. PubMed ID: 12673130
[No Abstract] [Full Text] [Related]
17. Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.
Suttorp M; Thiede C; Tauer JT; Range U; Schlegelberger B; von Neuhoff N
Haematologica; 2010 May; 95(5):852-3. PubMed ID: 20145269
[No Abstract] [Full Text] [Related]
18. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Perel JM; McCarthy C; Walker O; Irving I; Williams B; Kennedy GA
Haematologica; 2005 Nov; 90 Suppl():ECR25. PubMed ID: 16266916
[No Abstract] [Full Text] [Related]
20. Research on resistance to cancer drug Gleevec.
Sawyers CL
Science; 2001 Nov; 294(5548):1834. PubMed ID: 11732550
[No Abstract] [Full Text] [Related]
[Next] [New Search]
